The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans
- PMID: 3553525
- DOI: 10.1080/02681218780000041
The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans
Abstract
Candida albicans 6.4, which is resistant to both polyene and azole groups of antifungal antibiotics, has a larger lipid content and lower polar lipid to neutral lipid ratio compared with other strains that are sensitive or resistant only to azoles. C. albicans 6.4 contains a relatively greater proportion of triacylglycerol in its neutral lipid in the exponential phase of batch culture compared with other strains, but, unlike them, does not accumulate triacylglycerols or any other stored lipid in the stationary phase. Like other strains, in C. albicans 6.4 the major phospholipids are phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol, but sphingomyelin is absent; the major fatty acids are palmitic, palmitoleic, oleic and linoleic acids. In common with other C. albicans strains, strain 6.4 contains non-specific (lyso)phospholipase activity. The main distinctive feature of the lipid composition of C. albicans 6.4 is the absence of ergosterol, which is replaced by methylated sterol; mainly lanosterol, 24-methylene-24,25-dihydrolanosterol and 4-methylergostadiene-3-ol. It is suggested that the altered membrane sterol pattern provides a common basis for the double resistance by preventing polyene binding and reducing azole permeability.
Similar articles
-
The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans.J Gen Microbiol. 1986 Sep;132(9):2421-31. doi: 10.1099/00221287-132-9-2421. J Gen Microbiol. 1986. PMID: 3540203
-
Sterols in Candida albicans mutants resistant to polyene or azole antifungals, and of a double mutant C. albicans 6.4.Crit Rev Microbiol. 1987;15(1):111-5. doi: 10.3109/10408418709104454. Crit Rev Microbiol. 1987. PMID: 3319418 Review.
-
The lipid composition and permeability to the triazole antifungal antibiotic ICI 153066 of serum-grown mycelial cultures of Candida albicans.J Gen Microbiol. 1989 Jul;135(7):1949-55. doi: 10.1099/00221287-135-7-1949. J Gen Microbiol. 1989. PMID: 2693607
-
Two natural molecules preferentially inhibit azole-resistant Candida albicans with MDR1 hyperactivation.Chin J Nat Med. 2019 Mar;17(3):209-217. doi: 10.1016/S1875-5364(19)30023-8. Chin J Nat Med. 2019. PMID: 30910057
-
Molecular basis of resistance to azole antifungals.Trends Mol Med. 2002 Feb;8(2):76-81. doi: 10.1016/s1471-4914(02)02280-3. Trends Mol Med. 2002. PMID: 11815273 Review.
Cited by
-
Influence of methylfenpropidine on growth, sterol content and fatty acid composition of Candida albicans.Folia Microbiol (Praha). 2000;45(4):313-9. doi: 10.1007/BF02817553. Folia Microbiol (Praha). 2000. PMID: 11347252
-
Erg6 affects membrane composition and virulence of the human fungal pathogen Cryptococcus neoformans.Fungal Genet Biol. 2020 Jul;140:103368. doi: 10.1016/j.fgb.2020.103368. Epub 2020 Mar 19. Fungal Genet Biol. 2020. PMID: 32201128 Free PMC article.
-
Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.Antimicrob Agents Chemother. 1995 Nov;39(11):2378-86. doi: 10.1128/AAC.39.11.2378. Antimicrob Agents Chemother. 1995. PMID: 8585712 Free PMC article.
-
Lipidomics of Candida albicans biofilms reveals phase-dependent production of phospholipid molecular classes and role for lipid rafts in biofilm formation.Microbiology (Reading). 2011 Nov;157(Pt 11):3232-3242. doi: 10.1099/mic.0.051086-0. Epub 2011 Sep 8. Microbiology (Reading). 2011. PMID: 21903752 Free PMC article.
-
In vitro activity of a new antifungal triazole, D0870, against Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus.Antimicrob Agents Chemother. 1994 Nov;38(11):2553-6. doi: 10.1128/AAC.38.11.2553. Antimicrob Agents Chemother. 1994. PMID: 7872746 Free PMC article.